Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
Tofacitinib probably leads to lower withdrawals due to adverse events (5 mg/10 mg) compared with placebo (moderate certainty).
1 finding from 1 review
Toxicity (adverse events probably due to drug) · Patients with cancer receiving chemotherapy and/or radiotherapy
1 finding from 1 review
Toxicity (adverse events probably due to drug) · Patients with cancer receiving chemotherapy and/or radiotherapy
1 finding from 1 review
Toxicity (adverse events probably due to drug) · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in toxicity (adverse events probably due to drug) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Toxicity (adverse events probably due to drug) · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract showed no clear difference in toxicity (adverse events probably due to drug) compared with antifungal drugs not absorbed from GI tract; GRADE not reported.
1 finding from 1 review
Intervention not reported
Adverse events Adverse event episodes (n) reported · patients with treating osteoarthritis
The intervention probably leads to lower adverse events Adverse event episodes (n) reported (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events Adverse event episodes (n) reported · patients with treating osteoarthritis
The intervention showed no clear difference in adverse events Adverse event episodes (n) reported (moderate certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients who reported adverse events · Patients with a clinical and EEG diagnosis of BECTS
It is very uncertain whether the intervention changes proportion of patients who reported adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: a. hypoglycaemia (% of participants)
1 finding from 1 review
Adverse events for continuous vs standard regimen OCP · women with primary dysmenorrhoea
Combined low‐dose OCP may leads to higher adverse events for continuous vs standard regimen OCP compared with another combined low‐dose OCP (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events (number of adverse events/person/year) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
The intervention showed no clear difference in adverse events (number of adverse events/person/year) (low certainty).
1 finding from 1 review
Serious adverse events (classified by MedDRA) (Range of · infants
IPV‐OPV showed no clear difference in serious adverse events (classified by MedDRA) (Range of compared with OPV (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events Participants (n) reported adverse events · patients with treating osteoarthritis
The intervention showed no clear difference in adverse events Participants (n) reported adverse events (moderate certainty).
1 finding from 1 review
Adverse events Participants (n) reported adverse events · patients with treating osteoarthritis
It is very uncertain whether boswellia serrata changes adverse events Participants (n) reported adverse events compared with valdecoxib (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events Participants (n) reported adverse events · patients with osteoarthritis
The intervention showed no clear difference in adverse events Participants (n) reported adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events Participants (n) reported adverse events · patients with osteoarthritis
The intervention showed no clear difference in adverse events Participants (n) reported adverse events (moderate certainty).
1 finding from 1 review
Adverse events Participants (n) reported adverse events · patients with osteoarthritis
Persea gratissma + Glycine max (ASU 300 mg) showed no clear difference in adverse events Participants (n) reported adverse events compared with chondroitin sulphate (low certainty).
1 finding from 1 review
All‐cause serious adverse events 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review